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Background and Objectives. Inhibition of soluble fibrino-
gen binding to activated platelets represents the target of
pharmacologic approach with antagonists of the glyco-
protein IIb/IIIa (GPIIb/IIIa) complex. In this study we
assessed the effects of abciximab, a recombinant chimeric
Fab fraction of the antibody against GPIIb/IIIa, on sever-
al markers of platelet activation.
Design and Methods. The platelet surface expression of
GPIIb/IIIa was measured by a flow cytometry technique
using a two-color assay. GPIIb/IIIa was detected by FITC-
conjugated antibodies in whole blood, either unstimulat-
ed or exposed to platelet stimuli. The following antibodies
were used: CD41, which recognizes the IIb/IIIa complex
both in activated and non-activated conformers, and PAC-
1, which is directed toward the activated conformer of GPI-
Ib/IIIa. In addition, the same blood sample was incubat-
ed with CD62 antibody to measure P-selectin, as a mark-
er of α-granule degranulation. The effect of abciximab was
also assessed by experiments carried out on shear stress-
induced platelet aggregation, a test that appears to be a
predictor of platelet hemostatic function.
Results. Abciximab inhibited CD41 binding to glycoprotein
IIb (GPIIb) in a concentration-dependent manner and also
inhibited the binding of PAC-1 to active GPIIb/IIIa. In con-
trast, membrane-associated P-selectin was significantly
increased by the drug, which suggests that blockade of
GPIIb/IIIa receptors results in an increased platelet
degranulation in response to agonists. Shear stress-
induced platelet aggregation was inhibited by abciximab,
with a more pronounced effect on blood filtration, which
represents an index of platelet aggregate formation.
Interpretation and Conclusions. Our results indicate that
GPIIb/IIIa blockade by abciximab is accompanied by an
increase of α-granule secretion, suggesting that different
mechanisms regulate these aspects of platelet activation.
The described flow cytometry technique, that allows the
simultaneous in vitro detection of several platelet markers,
is a suitable method for assessing the effects of agents
which interfere with platelet function.
©2001, Ferrata Storti Foundation
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Platelets are essential for hemostatic control butthey are also implicated in the pathogenesis ofthrombosis. The initial adhesion of platelets to
thrombogenic surfaces such as damaged endothelium
or ruptured atherosclerotic plaques is a crucial event
that leads to platelet activation and to the formation
of platelet aggregates.1 Fibrinogen binding to the acti-
vated platelet receptor glycoprotein IIb/IIIa (GPIIb/IIIa)
plays a fundamental role in the formation of thrombi as
this event finally leads to homomeric platelet aggrega-
tion. The blockade of fibrinogen binding has been
recently addressed as a new therapeutic approach2-4
and antagonists of the platelet GPIIb/IIIa represent a
new class of antiplatelet agents.
Abciximab (c7E3, ReoPro®), the recombinant chimeric
(human/murine) Fab fraction of the antibody raised
against glycoprotein IIb/IIIa has been extensively stud-
ied from the bench to the bedside.5 Many clinical trials
have assessed its antithrombotic efficacy in several clin-
ical settings such as percutaneous transluminal coro-
nary angioplasty (PTCA), unstable angina and non-Q-
wave myocardial infarction.6-9 The efficacy of abcix-
imab was tested in several clinical trials7-11 which have
also highlighted the risk of major bleeding complica-
tions and established the superior safety and compara-
ble efficacy of abciximab in combination with a low-
dose, weight-adjusted, heparin regimen.12,13
Interindividual variation in response to abciximab has
been reported both in terms of extent and duration of
inhibition of platelet aggregation.14-16 Moreover, results
from one of these studies indicate that during therapy
with abciximab it is possible to identify cases in which
the inhibitory effect of the drug is not complete.14
Here we describe a simple and relatively rapid tech-
nique, based on the use of flow-cytometry, which
detects the effect of abciximab on several components
of platelet activation, such as the status of GPIIb/IIIa
receptors and α-granule degranulation. The effect of
abciximab was further investigated by experiments per-
formed on shear stress-induced platelet aggregation.
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Reagents
Abciximab (c7E3F(ab)2, ReoPro®) was purchased from
Centocor/BV (Leiden, Netherlands). Adenosine-5-di-
phosphate (ADP), the stable thromboxane analog
U46619 and recombinant hirudin (r-hirudin) were pur-
chased from Sigma. The peptide TRAP (SFLLRN) which
represents the first six residues of the tethered throm-
bin receptor ligand was from Bachem (Heidelberg, Ger-
many). Quantum Simply Cellular® microbeads were from
Flow Cytometry Standards Corp. (FCSC, San Juan PR,
USA).
Antibodies
The monoclonal R-phycoerythrin (PE)- and fluores-
cein isothiocyanate (FITC)-conjugated antibodies CD42b
and CD41, as well as isotype mouse IgG1 were from
Coulter-Immunology (Hialeah, FL, USA). FITC-conjugat-
ed CD62 was from Ortho Clinical Diagnostics (Raritan,
NJ, USA). The FITC-conjugated antibody PAC-1 was from
Becton Dickinson, (San Josè, CA, USA). CD42b antibody
is directed against an activation-independent epitope
characteristic of the α-subunit of GPIb17 and allows the
selection of platelets from among other blood cells.
CD41 is directed against the IIb subunit of the GPIIb/IIIa
complex, thus recognizing the IIb/IIIa complex both in
activated and non-activated conformers.18 PAC-1 binds
to a conformation-dependent determinant on activat-
ed GPIIb/IIIa complexes unoccupied by adhesive pro-
teins.19,20 CD62 recognizes P-selectin exposed on platelet
membrane.
Blood collection
Blood was collected from 14 healthy donors (6 males
and 8 females) by venipuncture using a 19-gauge needle
and minimal stasis. Donors were between 25 and 55 years
of age and had not taken any drugs for at least 15 days
before blood sampling. After informed consent had been
obtained, blood was drawn into plastic syringes and the
first 5 mL were discarded. The blood was anticoagulated
with 3.8% trisodium citrate (9:1 v/v) for the flow cytom-
etry assays, whereas for the aggregation test the blood
was anticoagulated with 500 U/mL r-hirudin. Flow
cytometry and aggregation assays were performed with-
in 1 h of blood collection. Platelet counts were performed
using a Sysmex-Toa counter (Dasit, Cornaredo, Italy).
Platelet markers were assessed in blood from 9 out of
the 14 subjects. The concentration-response curve of
abciximab was constructed for the blood from 5 subjects.
Platelet preparation for flow cytometric
analysis
Whole blood was diluted with PBS to obtain 1×106
platelets/100 µL. Samples were exposed to abciximab or
buffer for 45 min at room temperature and subsequently
incubated for 15 min with agonists at room tempera-
ture. ADP, TRAP or U46619 were dissolved in saline and
used at 10, 35 and 2 µM, final concentration, respec-
tively. Last, platelets were incubated at room tempera-
ture for 20 min with saturating concentrations (10-20
µL) of the FITC- and PE-conjugated antibodies for flow
cytometric analysis. The reaction was stopped with cold
PBS (700 µL).
Analysis of platelets by flow cytometry
Flow cytometric measurements were performed with
a FACS Calibur flow cytometer (Becton-Dickinson),
equipped with a 15 mW air-cooled 488-nm argon ion
laser. The fluorescence signals of FITC and PE were
detected with 530/30 nm (channel 1) and 585/42 nm
band pass filters (channel 2) with correction of the spec-
tral overlap by color compensation. The calibration of
the flow cytometer was performed using standard flu-
orescent microbeads (CaliBRITE®, Becton Dickinson, San
Josè, CA, USA). Quantum Simply Cellular, which is a mix-
ture of four highly uniform microbead populations of
the same size characterized by increasing capacities to
bind mouse monoclonal IgG antibodies, was used to
quantify antibody binding to platelets. The mixture
includes a population of microbeads (blank) which does
not bind the mouse IgG. Labeling the microbeads with
a specific antibody creates a set of standards that can
be used to calibrate the instrument's response to the
antibody. To exclude the interference of erythrocytes
and leukocytes, platelets were gated in the forward scat-
ter versus fluorescence 2 dot-plot based on the high
expression of CD42bPE. Fluorescence histograms were
obtained for 10,000 CD42b positive platelets/sample
recorded at a flow rate of approximately 500 cells/sec. 
The FITC positive events (GPIIb/IIIa, GPIIb/IIIa in acti-
vated form or P-selectin) were determined in this pop-
ulation. Histograms were composed from fluorescence
data obtained using a logarithmic scale of amplifica-
tion. Mean FITC- and PE-fluorescence intensities were
calculated from fluorescence histograms for the gated
population and data analyzed by CELLQuest software
(Becton-Dickinson). The results are expressed as anti-
body binding capacity (ABC, arbitrary units converted to
a linear scale). The gate for activated platelets was set
in order to include <1% of the events seen when iden-
tical platelet samples were incubated with the control
murine IgG used at the same concentration as the
murine monoclonal antibodies. 
In experiments carried out with abciximab, increasing
concentrations of the drug were incubated with whole
blood for 45 min. The IC50 for abciximab was calculated
by plotting abciximab concentrations versus the per-
cent inhibition of ABC.
Blood filtration test
Whole blood was used for the filter test. The device
and technique used to perform the test have been
already described.21 Briefly, 5 mL of anticoagulated
whole blood, previously incubated with abciximab or
saline for 45 min, were forced at a constant pressure of
100 mmHg (room temperature) through a capillary-
sized channel of polycarbonate glass-fiber (Pall U100;
Pall Process Filtration, Portsmouth, UK). The glass-fibers
(diameter 0.1-3.4 µm) retain particles with a diameter
> 10 µm. The instrumentation (A.B.S. UK Ltd., Fareham,
Platelet GPIIb/IIIa and abciximab
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Hampshire, England) automatically displays the num-
ber of drops passing through the filter per time unit (5
sec). The number of platelets retained by the filter was
calculated by difference between the platelet count
before and after filtration in blood collected into EDTA-
containing tubes. Platelet count was monitored up to
600 sec at which time blood filtration was blocked. 
Statistical analysis
Results are presented as the mean ± SEM. Signifi-
cance of differences was analyzed by ANOVA followed
by Tukey's test. 
Results
Effect of abciximab on GPIIb/IIIa in unstimu-
lated platelets and platelets exposed to ago-
nists
Platelets were identified in PBS-diluted whole blood
based on the expression of the constitutive glycoprotein
IIb using a PE-conjugated monoclonal antibody CD42b.
In resting platelets, GPIIb expression, recognized by
CD41, was higher than that of functionally active GPI-
IIb/IIIa conformer (not shown). The effect of ADP, TRAP-
6 and U46619 on platelets was determined in whole
blood exposed to each agonist for 15 min. This incuba-
tion time was selected on the basis of preliminary exper-
iments indicating that the expression of adhesive mol-
ecules reached a plateau within 10 min after the addi-
tion of the stimulus. All the agonists used induced a
characteristic activation-dependent shift to the right of
the tracings of PAC-1 binding to platelets, compared
with the resting condition (not shown). The same ago-
nists, as expected, scarcely affected the constitutive
expression of GPIIb/IIIa in resting platelets, measured
as CD41 binding to GPIIb (not shown). The effects of
agonists on the expression of both GPIIb/IIIa conform-
ers were quantified and the results are shown in Figure
1. In preliminary experiments, abciximab was incubat-
ed with blood for 5 to 60 min. The results were that
abciximab inhibited CD41 binding to GPIIb in resting
platelets and that the effect was complete within 30-
45 min of incubation. In this condition, an IC50 value of
1.67 µg/mL, determined on the basis of a concentra-
tion-response curve was calculated (Figure 2). There-
fore, a concentration of 2.5 µg/mL abciximab was
selected and used for all the experiments. Abciximab, at
this concentration, inhibited both CD41 and PAC-1
binding to platelets (Figure 3). 
Effect of abciximab on P-selectin 
CD62 binding to P-selectin was not affected by abcix-
imab in resting platelets (Figure 4), whereas it increased
Figure 1. Effect of agonists on CD41 and PAC-1 binding to
platelets in whole blood. Whole blood was diluted with PBS
to obtain 1× 106 platelets/100 µL and samples were incu-
bated for 15 min with TRAP-6 (35 µM), ADP 10 (µM) and
U46619 (2 µM) at room temperature. Samples were then
incubated for 20 min with saturating concentrations (10-20
µL) of the FITC- and PE-conjugated antibodies for flow cyto-
metric analysis. Incubation with isotypic control before addi-
tion of conjugated mAbs did not affect binding of antibod-
ies. Data are expressed as antibody binding capacity (ABC)
and are the mean ± SEM of 9 individual samples. *p <0.01
versus unstimulated.
Figure 2. Concentration-dependent effect of abciximab on
CD41 binding to platelets. Abciximab (0.01-20 µg/mL) was
incubated with whole blood for 45 min. Samples were then
incubated for 20 min with saturating concentrations of the
FITC-conjugated antibody CD41 for flow cytometric analy-
sis. Data are expressed as mean ± SEM of 5 experiments
performed on blood from different donors.
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significantly after blood exposure to TRAP-6 and
U46619 (1,232.5±197.8% and 947.1±155.8% increase
over basal, respectively). The effect of ADP was less pro-
nounced (481.2±111.8% increase over basal). Abcix-
imab, pre-incubated with blood before the addition of
ADP, TRAP-6 and U46619 increased P-selectin expres-
sion. The increase was statistically significant when ADP
or U46619 was used as the stimulus (p <0.05 versus
corresponding controls not exposed to abciximab) (Fig-
ure 4).
Effect of abciximab on shear stress-induced
platelet aggregation
Blood filtration of untreated samples (5 mL) occurred
as a function of time, with a residual blood volume of
2.23±0.74 mL, n=9, measured at 600 sec. The filtration
of samples treated with abciximab was complete with-
in 83±1.53 sec, n=9 (Figure 5).
Figure 5, panel a, shows an example of shear stress-
induced platelet aggregation in treated and untreated
blood samples from a single donor. This aggregation was
measured by the number of blood drops which passed
through the filter within 600 sec. Shear stress-induced
aggregation was also quantified by the extent of platelet
retention on the filter, evaluated at different time inter-
vals. In untreated blood, the percentage of platelet
retention was almost complete (84.0±5%, n=9) 40 sec
after the beginning of the experiment. Abciximab sig-
nificantly reduced it by more than 50% (Figure 5, pan-
el b).
Discussion
Here we describe a flow cytometric assay that allows
the simultaneous evaluation of the expression of both
conformers of GPIIb/IIIa and of P-selectin in whole
blood. The advantages of this technique are essentially:
Figure 3. Individual respons-
es of samples from 9 differ-
ent donors to the effect of
abciximab in terms of CD41
and PAC-1 binding to
platelets. Samples, incubat-
ed for 45 min with abciximab
and subsequently exposed
to agonists or buffer for 15
min, were treated for flow
cytometric analysis as
described in Figure 1. Data
(mean ± SEM) are expressed
as percent inhibition exerted
by 2.5 µg/mL abciximab in
whole blood samples from 9
donors.
Figure 4 (left). Effect of abciximab on CD62 binding to
platelets. Whole blood was incubated for 45 min with buffer
or abciximab (2.5 µg/mL). Samples were then exposed to
agonists (see Figure 1) and subsequently treated for flow
cytometric analysis. Data are expressed as mean ± SEM,
n=9, of antibody binding capacity (ABC). *p <0.05 versus
corresponding samples not exposed to abciximab.
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a) small amount of blood needed;
b) time saving;
c) possibility of using whole blood, which greatly
reduces platelet activation due to sample manipulation
and avoids the loss of large platelets in the preparation
processes;
d) widespread feasibility (due to the utilization of
commercially available antibodies).
Our results indicate that the response of platelets
from healthy volunteers to the inhibitory effect of abcix-
imab is characterized by a degree of interindividual vari-
ability, a finding that is in accordance with that report-
ed by others.22 This aspect might be more relevant in a
pathologic setting in which the initial levels of activat-
ed platelets are globally much greater than those seen
for healthy subjects. Indeed, a marked interpatient vari-
ability in response to abciximab has also been detected
during and after the drug administration to patients
with coronary artery disease selected for PTCA.14 This
variability is, therefore, an important feature that must
be taken into account in view of a refinement of dosing
for prolonged therapy and for the evaluation of unoc-
cupied receptors prior to invasive procedures. From this
study it emerges that abciximab markedly increased the
extent of P-selectin expressed on activated platelet sur-
face. This observation indicates that GPIIb/IIIa blockade
does not inhibit, and indeed may even increase α-gran-
ule secretion, thus suggesting a discoupling between
the effect of abciximab on platelet aggregation and
secretion, as suggested by others.23 It can, therefore, be
concluded that different mechanisms regulate platelet
granule secretion and platelet aggregation. A potentia-
tion of ADP-induced α-granule degranulation, detect-
ed by surface expression of P-selectin, has been
described by Schneider et al. in response to abciximab.24
These authors postulated that fibrinogen, via a mecha-
nism independent of its binding to GPIIb/IIIa, is respon-
sible for this effect. On the basis of these considerations
it can be envisaged that GPIIb/IIIa receptor blockade by
abciximab increases fibrinogen availability, thus induc-
ing platelet degranulation in response to agonists. The
finding of increased P-selectin exposure in activated
platelets following incubation with abciximab might
explain the observation of increased P-selectin expres-
sion during abciximab infusion in platelets from some
patients with coronary artery disease who had under-
gone PTCA.14 P-selectin exposed on activated platelets
mediates platelet interaction with leukocytes and there-
fore has a prominent role in the cross-talk between
blood cells. It drives the first step (rolling) in leukocyte
extravasation during the inflammatory response and the
platelet adhesion to microvascular endothelium during
post-ischemic reperfusion.25,26 P-selectin increase in
platelets, due to blockade of GPIIb/IIIa, can promote
platelet-leukocyte or platelet-endothelial cell interac-
tion with accumulation of pro-inflammatory chemo-
kines and consequent amplification of ischemic damage.
Abciximab, on the other hand, has been shown to reduce
the interaction of platelet-leukocyte aggregates with
the microvasculature and to limit inflammatory respons-
es during reperfusion by inhibiting the surface expres-
sion of MAC-1. This effect has been observed in an ani-
mal model of myocardial reperfusion injury after coro-
nary occlusion27 as well as in patients with acute myo-
cardial infarction.28
On the basis of these considerations it is not easy to
predict the clinical relevance of P-selectin increase in
response to abciximab.
In this study the effects of abciximab were confirmed
by experiments carried out on shear stress-induced
platelet aggregation, a test that appears to be a predic-
tor of platelet hemostatic function.21 Abciximab, at con-
centrations completely blocking platelet GPIIb/IIIa,
markedly increased blood filtration, which indicates that
shear stress-induced platelet aggregation is dependent
on the GPIIb/IIIa glycoprotein complex. Platelet reten-
tion on the filter, was, instead, reduced only in part (by
fifty percent), suggesting that aspects of blood cell
interaction other than platelet aggregation might be
Figure 5. An example of the effect of abciximab on shear
stress-induced platelet aggregation. Panel a. Platelet aggre-
gation was measured by the number of blood drops passed
through the filter within 600 s in untreated blood samples
(open circles) and in samples treated with abciximab (filled
squares). For details see Design and Methods. Panel b.
Platelet retention on the filter measured 40 s after the
beginning of the test, in blood samples either untreated
(open column) or treated with abciximab (filled column).
Data are expressed as percent of platelet retention and are
the mean + SEM of 9 single experiments. *p <0.01 versus
untreated samples.
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involved in this phenomenon. The increased availability
of P-selectin on platelets exposed to abciximab might
increase the extent of platelet-leukocyte aggregates,
thus influencing platelet retention. 
The described technique, that simultaneously detects
in vitro the effect of abciximab on GPIIb/IIIa and on
platelet α-granule secretion, represents a useful tool in
order (i) to characterize the profile of platelet activation
(ii) to assess the potentially paradoxical effect of agents
interfering with platelet function.
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Potential implications for clinical practice
We have assessed the effects of the GPIIb/IIIa recep-
tor inhibitor abciximab on platelet activation by a
flow cytometry technique that allows the simulta-
neous in vitro detection of both conformers of GPI-
Ib/IIIa and of P-selectin. Results indicate that the
extent of GPIIb/IIIa blockade is characterized by
interindividual variability and results in an increase
of P-selectin, indicating that platelet aggregation
and secretion are regulated by different mechanisms.
This technique is therefore useful to characterize the
profile of platelet activation and to assess the poten-
tially paradoxical effect of agents interfering with
platelet function.
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